Further data analyses from trials investigating EGFR inhibitor efficacy, revealed that patients who developed skin rash during erlotinib treatment (an established adverse effect of drugs that target EGFR signalling) had considerably improved prognosis with 1-year survival rates beyond 40%, comparable with previous reports for FOLFIRINOX [63,65,66,67]. This evidence concerns the gene EGFR and exanthem.